Sequential Immune Adjuvant and Monoclonal Antibody Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting cancer tumor growth, particularly in ovarian cancer, are inadequate as they fail to show significant improvements in progression-free survival or overall survival when combining chemotherapy with immunotherapy, and the optimal duration of immunization remains unclear.
Innovation Solution
A method involving sequential administration of an immune adjuvant and a therapeutic monoclonal antibody specific for a tumor-associated antigen, with specific combinations such as carboplatin and TAXOL, and immune homeostatic checkpoint inhibitors, administered over a defined treatment schedule to enhance immune response and inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemotherapy is combined with immunotherapy (monoclonal antibody), then initial response rate is improved, but progression-free survival and overall survival do not show significant improvement
Solution Approach 1:
The patent applies preliminary action by administering the immune adjuvant (chemotherapy) before the therapeutic monoclonal antibody. The chemotherapy treatment is given first to reduce tumor burden and potentially enhance immune visibility, followed by the monoclonal antibody treatment. This sequential approach aims to create optimal conditions for the immune system to recognize and attack tumor cells, thereby improving both initial response and long-term survival outcomes.
Solution Approach 2:
The patent implements periodic action through a structured treatment schedule with multiple cycles. The treatment consists of repeated administrations of chemotherapy followed by monoclonal antibody over several cycles (e.g., 6 cycles of chemotherapy followed by continued monoclonal antibody). This periodic regimen allows for sustained immune stimulation and tumor control, addressing the limitation of single-agent or simultaneous administration approaches.
2Reliability
If monoclonal antibody is administered alone after chemotherapy, then immune response is stimulated, but optimal duration of immunization remains unclear and clinical outcome is not improved
Solution Approach 1:
The patent employs feedback mechanisms by monitoring clinical response and immune markers during treatment. The treatment duration and dosing schedule are optimized based on observed patient responses, allowing adjustment of the immunization duration to achieve optimal clinical benefit. This feedback-driven approach helps determine the optimal treatment duration by evaluating progression-free survival and overall survival outcomes at different time points.
Solution Approach 2:
The patent applies parameter changes by systematically varying treatment parameters including the timing, duration, and dosing frequency of both chemotherapy and monoclonal antibody administration. The study evaluates different treatment schedules (e.g., varying the number of chemotherapy cycles, the interval between chemotherapy and monoclonal antibody, and the total duration of immunotherapy) to identify the optimal parameter combination that maximizes survival benefit while minimizing treatment-related toxicity.
3Reliability
If simultaneous administration of monoclonal antibody and chemotherapy is used, then immune response is enhanced, but the benefit of combination therapy remains unclear without control group
Solution Approach 1:
The patent applies segmentation by dividing the treatment into distinct sequential phases rather than simultaneous administration. The treatment is segmented into an initial chemotherapy phase followed by a monoclonal antibody phase, with clear temporal separation between the two modalities. This segmentation allows for independent evaluation of each treatment's contribution while maintaining the combination therapy approach, and enables comparison with historical control data from single-agent studies.
Data Source
AI summary
The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and b) administering to the patient the immune adjuvant; and a final treatment consisting of administering to the patient the therapeutic monoclonal antibody specific for a tumor associated antigen, wherein time between step a) and step b) is a time sufficient for treatment of the patient with the immune adjuvant, and wherein time between the step b) and the final treatment is from about 10 to about 14 weeks.